154
Participants
Start Date
March 1, 2016
Primary Completion Date
March 17, 2021
Study Completion Date
March 17, 2021
Vinorelbine
Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
Active Symptom Control
Wales Cancer Trials Unit, Cardiff
Collaborators (1)
Pierre Fabre Laboratories
INDUSTRY
Wales Cancer Trials Unit
OTHER